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ations were obtained between marker ratios of bone metabolism
and change in cartilage volume.
Conclusions: The results of this study suggest that overall, lower
serum levels of bone metabolism in osteoarthritis may be pre-
dictive of cartilage loss. Further insight into understanding how
individual markers of bone metabolism affect cartilage loss may
facilitate understanding of the pathogenesis of this disease and
aid in predicting disease progression
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THE EFFECTS OF ENDOMEDULLAR IMPLANTS ON THE
PERIOSTEAL VESSEL STRUCTURES OF THE RAT TIBIA
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Purpose: The healing of bones is successfully achieved after
intramedullar fracture-fusing techniques after fractures or surgery
despite the deﬁnite impairment of peri- and endosteal microcircu-
lation. Prostheses used for surgical treatment of hip osteoarthritis
also impair endosteal circulation. Based on these observations
several authors have proposed that the connection between peri-
and endosteal components of the microcirculation is of minimal
importance in long canaliculated bones. Alternatively, we hypoth-
esized that the reduced efﬁcacy of the endosteal circulation may
be overcome by a compensatory hypertrophy of the periosteal
circulation.
To test this presumption, we intended to answer the following
questions:
1. To what extent does the impairment of the endosteal circulation
modify the density of periosteal vasculature?
2. Is there any impact of drilling the medullar cavity and placement
of intramedullar implant on the density of periosteal circulation?
3. Does the implant material inﬂuence the changes in periosteal
vasculature?
Methods: In female Wistar rats, the medullary cavities of tibias
were drilled out with a series of microdrills (after opening the
proximal metaphyseal cortices of the shin bones) and implants
of different material (polyethylene or titanium) were inﬁxed tightly
into the moulded cavity. Endomedullary vasculature was injured
also by drilling or remained intact in the contralateral tibias. After
a 3-months follow up period, the anteromedial and anterolateral
surfaces of tibial periosteum were exposed under an operating
microscope, and the periosteal microarchitecture was examined
with a Cytoscan A/R-type intravital videomicroscope. Vessel den-
sity of the anteromedial and anterolateral surfaces of tibial pe-
riosteum was evaluated by using an image analyzer computer
software.
Results: Endomedullary drilling (without implants) did not induce
periosteal vascular density changes (total vessel length/examined
area). Higher vascular density was observed in the anterome-
dial and anterolateral periosteum (by 40% and 70%, respectively;
p<0.001) in bones with polyethylene endomedullary implants as
compared to those of the intramedullarly drilled contralateral tib-
ias. With titanium implants, however, the vascular density in the
periosteum was only 20% higher (ns). A moderate, albeit not
signiﬁcant increase in the ratio of larger diameter vessels in the
periosteum was seen in response to endomedullar drilling and
titanium inﬁxing. In polyethylene implants, however, the direction
of changes was opposite as the ratio of large vessels did not
increase, but rather decreased by ∼20%, suggesting the predom-
inance of smaller-diameter vessels in the periosteum.
Conclusions: Surgical damage of the endosteal vessels itself
did not induce signiﬁcant changes in the vascular structure of
the rat periosteum. Placement of endomedullar implants, however,
induces an enhanced vessel formation in the periosteal com-
partment. The quality of the implant has a strong inﬂuence on
these structural changes. Speciﬁcally, polyethylene brings about
a marked increase in periosteal vasular density with a concomi-
tantly increased ratio of small vessels. Our results suggest that the
biologically inert endomedullar titanium causes less pronounced
compensatory vessel hypertrophy in the periosteum as compared
to polyethylene. These results can be linked to the lower osteo-
integrative properties of polyethylene; such material may inhibit
the regeneration of the endosteal vessels which is compensated
by vascular neogenesis reactions of the periosteum.
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Purpose: Rheumatoid arthritis is characterized by synovial hy-
perplasia, inﬂammatory inﬁltration, cartilage destruction and juxta-
articular as well as generalized bone demineralization. Since the
discovery of their ability to mediate the pleiotropic effects of
xenobiotics and fatty acid peroxisome proliferators in rodents, per-
oxisome proliferators-activated receptors (PPARs) have emerged
as key regulator of lipid metabolism in humans. PPARs are mem-
bers of the nuclear hormone receptor superfamily which behave
as ligand-activated transcription factors in response to endoge-
nous fatty acids and eicosanoids or isotype-selective synthetic
compounds as ﬁbrates or thiazolidinediones. In this last decade,
increased evidence has shown a role of their three isotypes in
inﬂammatory modulation. We and others demonstrated previously
that PPAR gamma agonists reduced the severity of experimental
polyarthritis and the overall bone loss. In the present study, we in-
vestigated the effect of pioglitazone on inﬂammatory-induced dem-
ineralization and bone microarchitecture in arthritic rats, and the
possible contribution of the osteoclastogenesis mediators RANKL
and IL-17.
Methods: Lewis rats were sensitized by an intra-dermal injection
of 1 mg of complete Freund’s adjuvant (CFA) at the basis of the tail
and were treated orally for 21 days with 30 mg/kg/d pioglitazone, or
with vehicle only. Arthritis severity was evaluated by clinical scor-
ing and histological examination. Bone mineral density (BMD) of
three regions of interest (lumbar spine, right and left femurs) was
measured by dual-energy X-ray absorpsiometry (DEXA) before
sensitization and at day 20. Micro-computed tomography (micro-
CT) analysis of femur was performed to measure mean cortical
height at three different points. Bone volume fraction (BV/TV),
trabecular thickness (Tb.Th), trabecular number (Tb.N) and tra-
becular separation (Tb.Sp) were calculated. Circulating levels of
soluble RANKL, and IL-17 were determined using commercially
available immunoassays.
Results: Treatment with pioglitazone, beyond its ability to reduce
arthritis severity, revealed a major protecting effect on bone ero-
sion, as supported by the histological grading of ankle joints.
Pioglitazone was effective in preventing bone resorption in arthritic
animals as: i) BMD values in all ROIs of treated animals were sig-
niﬁcantly higher compared to BMD values of vehicle-treated con-
trols, ii) femoral cortical bone thickness was preserved markedly
S94 Poster Presentations
in secondary spongious zone and diaphyseal cortical bone and
slightly in primary spongious area, and iii) bone microarchitecture
showed higher values of BV/TV, Tb.th, Tb.N and lower value of
Tb.Spin treated rats. Finally, we demonstrated that the overproduc-
tion of RANKL and IL-17 in sera of arthritic animals was prevented
by pioglitazone treatment.
Conclusions: In the present study, we demonstrated that pi-
oglitazone had bone protective properties in arthritis-induced in-
ﬂammation. The concomitant decrease of circulating IL-17 and
RANKL levels strongly suggests that pioglitazone anti-resorptive
effect is likely supported by the modulation of the IL-17-RANKL
osteoclastogenesis pathway.
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Purpose: Studies of animal models of osteoarthritis undergoing
anti-resorptive therapy have suggested that inactivation of bone re-
sorption leads to improved articular cartilage status. However, the
role of osteoclasts, and subchondral bone turnover, still remains
to be elucidated. In alignment, an increasing amount of research
is devoted to the cellular phenotype associated with disease sta-
tus. The osteoclast phenotype associated with osteoarthritis has
not been investigated. We developed a pure human osteoclast
system, and investigated the cellular phenotype on various bone
substrates; cortical, trabecular and calcitﬁed cartilage.
Methods: CD14+ monocytes were isolated from human peripheral
blood using a ﬁcoll gradient and magnetic sorting. For investigation
of osteoclastogenesis the CD14+ cells were seeded on either
cortical bovine bone slices or plastic with 25ng/mL RANKL and M-
CSF in the presence or absence of 17β-estradiol (0.001-10nM) and
cultured for 21 days. For mature human osteoclast experiments
CD14+ cells were cultured in ﬂasks for 10 days, and the lifted and
reseeded onto different matrices and cultured for another 10 days
in the presence or absence of well-characterized bone resorption
inhibitors (calcitonin (1nM-1μM), ibandronate (1μM) and diphyllin
(300nM)). Osteoclastogenesis was assayed using the osteoclast
marker Tartrate Resistant Acid Phosphatase (TRACP), as well
as TRACP staining. Bone resorption was assayed by calcium
release and CTX-I (C-terminal Telopeptide of Type I Collagen) all in
cell culture supernatants. Immunocytochemistry for the calcitonin
receptor (CTR) and TRACP was performed on both precursors
and mature osteoclasts on bone. Finally, mature osteoclasts were
seeded on calciﬁed cartilage from bovine knee joints, human
trabecular bone from vertebrae and human cortical bone from
femurs in the presence or absence of resorption inhibitors.
Results: Osteoclastogenesis was clearly seen when measuring
TRACP, CTX-I and calcium release, with TRACP release initiated
on day 5 of culture and CTX-I and calcium release on day 7.
All markers were increased more than 500% (P<0.01), compared
to initial values. TRACP staining conﬁrmed the presence of large
multinucleated TRACP positive cells. For the mature human os-
teoclasts intense bone resorption was observed within 24 hours
after seeding on bovine bone slices, and bone resorption was
attenuated by more than 70% in the presence of the resorption
inhibitors (P<0.01). Immunocytochemistry for CTR and TRACP
clearly demonstrated the presence of mature osteoclasts. Inter-
estingly human osteoclasts also resorbed the calciﬁed cartilage,
the human trabecular and cortical bones, although differences
in the level of resorption were observed, suggesting an induc-
tion of distinct osteoclast phenotypes that is dependent on the
extracellular matrix at which they are activated.
Conclusions: We have demonstrated that CD14+ monocytes iso-
lated from human peripheral blood are a highly useful source of
osteoclasts, which are characterized by expression of the CTR,
TRACP and bone resorption, all which are hallmarks of osteo-
clast function. We used this high quality osteoclast preparation to
demonstrate that osteoclasts resorb calciﬁed cartilage, and since
this process is involved in the pathogenesis of OA this system
can be used for characterizing osteoclast related effects on joint
turnover.
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Purpose: We have reported that the impairment of osteoclast
fusion had important roles for the delayed fracture healing in
streptozotocin (STZ)-induced diabetic mice. In this study, we fur-
ther investigated the mechanism of the malfunction of diabetic
osteoclasts using genetic analysis in vivo and cell culture in vitro.
Methods: The C57BL/6 mice were irradiated (9 Gy) and injected
with 4 × 106 bone marrow cells isolated from C57BL/6-EGFP
mice. The diabetes was induced by intravenous administration of
STZ (150 mg·kg-1 in mice). The control was injected with sodium
citrate buffer. At 6 weeks after transfer, bone marrow cells were
isolated from both the STZ and control groups, and then cultured
in the 96well dish with the cortical bone plate. The cortical bone
plates were extraction skull bones of wild type C57BL/6, and those
were ﬁxed and dehydrated with 100% ethanol. The cell culture was
performed in DMEM supplemented with 10% fetal bovine serum
under 5% CO2 and 95% air at 37 °C, and the ﬂoating cell was
removed after 2 h incubation. On day 3, 5, and 7, the cortical bone
plates were examined to analyze the formation of the resorption
pits by a scanning electron microscope.
The standardized closed fracture models were created in both the
control and STZ group. At 2 weeks after the fracture, the frozen
sections of the fracture site were created. The osteoclasts at
callus area were captured by laser capture microdissection (LCM).
We extracted RNA and synthesized cDNA by using commercial
kit. RT-PCR was performed to evaluate the mRNA expressions
of MMP9, Catepsin-K, Receptor activator of NF-kappaB (RANK),
dendritic cell-speciﬁc transmembrane protein (DC-STAMP), and
GAPDH.
